Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

AIM: To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations. METHOD: Western...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bain, Gretchen, King, Christopher D., Schaab, Kevin, Rewolinski, Melissa, Norris, Virginia, Ambery, Claire, Bentley, Jane, Yamada, Masanori, Santini, Angelina M., van de Wetering de Rooij, Jeroen, Stock, Nicholas, Zunic, Jasmine, Hutchinson, John H., Evans, Jilly F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2013
Gaiak:
Pharmacodynamics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575944/
https://ncbi.nlm.nih.gov/pubmed/22803688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04386.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak